S&P 500
7,430.40
+0.40%
Dow Jones
52,093.40
+0.46%
Nasdaq 100
29,875.90
+1.17%
Russell 2000
3,004.01
+0.73%
FTSE 100
10,476.30
+0.14%
Nikkei 225
70,979.70
+2.40%
Live: Will Micron Crush Q3 Earnings Tonight After Tuesday’s 13% Selloff?

Health and Healthcare

Oracle Buys Drug Trial Software Firm (ORCL)

Photo of Paul Ausick
By Paul Ausick Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Oracle Corp. (NASDAQ: ORCL) has announced that it will acquire ClearTrial, a maker of cloud-based Clinical Trial Operations applications for an undisclosed sum. The transaction is expected to close in the first half of this year. The companies will continue to operate separately until the transaction is closed according to the Oracle announcement.

ClearTrial’s clinical trial applications “will add leading budgeting, forecasting, and analytics capabilities that help plan, source, and track clinical projects,” according to an Oracle overview of the transaction. Oracle plans to integrate ClearTrial’s solutions into its Health Sciences applications portfolio.

Oracle shares are trading down fractionally at $29.34 in a 52-week range of $24.72-$36.50.

Follow 24/7 Wall St. on Google
Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Only 30% of Americans Ever Receive an Inheritance. Those Who Do Get It at 58, Not 30.
David Beren |

Only 30% of Americans Ever Receive an Inheritance. Those Who Do Get It at 58, Not 30.
Enroll in Medicare at 65 While Still Working and Your HSA Deposits Turn Into a 6% Penalty
Drew Wood |

Enroll in Medicare at 65 While Still Working and Your HSA Deposits Turn Into a 6% Penalty

Continue Reading

Douglas A. McIntyre |

Pre-Market Stock News (MAR 21, 2007)

(ABN) ABN AMRO could get late stage bids from rivals according to WSJ.(ADBE) Adobe traded up 5% after beating earnings…

Can the 800% Gain in Immuron Be Rationalized Very Easily?
Jon C. Ogg |

Can the 800% Gain in Immuron Be Rationalized Very Easily?

The day traders are back at it, chasing stocks on news with very few thoughts about what the fundamentals may…

What This FDA Update Means for Equillium’s COVID-19 Study
Chris Lange |

What This FDA Update Means for Equillium’s COVID-19 Study

Equillium shares jumped on Friday after the company announced a key update from the FDA regarding its late-stage COVID-19 trial.

Massive Biopharma Movers of the Past Week
Chris Lange |

Massive Biopharma Movers of the Past Week

A few biopharma stocks made massive runs over the course of this past week, some losing more than half their…

Is the FDA’s Hold on Inovio’s COVID-19 Vaccine Study Too Much?
Chris Lange |

Is the FDA’s Hold on Inovio’s COVID-19 Vaccine Study Too Much?

Things aren’t looking up for Inovio Pharmaceuticals, after the FDA notified the company that it was placing a partial hold…

Chris Lange |

5 Big FDA Decisions Expected in September

24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of September and…

BioCryst Pharmaceuticals Announces Secondary Offering
Chris Lange |

BioCryst Pharmaceuticals Announces Secondary Offering

BioCryst Pharmaceuticals watched its shares fall handily on Tuesday after the firm announced a secondary offering.

4 Companies That Destroyed Shareholders Despite a Brexit Recovery
Chris Lange |

4 Companies That Destroyed Shareholders Despite a Brexit Recovery

Despite Brexit absolutely rocking the market over a week ago, the broad markets made a solid comeback leading most people to…

Aclaris Files for Secondary Offering
Chris Lange |

Aclaris Files for Secondary Offering

Aclaris Therapeutics saw its shares make a handy gain on Friday after the company announced the pricing of its secondary…

Top Gaining Stocks

Builders FirstSource
BLDR • Vol: 3,494,660
Mohawk Industries
MHK • Vol: 1,344,631
IQVIA
IQV • Vol: 1,813,368
Charles River Laboratories
CRL • Vol: 936,620
United Airlines
UAL • Vol: 10,071,273

Top Losing Stocks

Coterra Energy
CTRA • Vol: 73,319,495
Apollo Global Management
APO • Vol: 6,885,209
Blackstone
BX • Vol: 7,663,168
Coinbase
COIN • Vol: 9,443,260
Principal Financial Group
PFG • Vol: 2,648,240